In Brief: Cortecs/Osteometer BioTech agreement
This article was originally published in The Gray Sheet
Executive SummaryCortecs/Osteometer BioTech agreement: U.K.-based oral drug delivery firm Cortecs inks a development deal with Danish diagnostics firm Osteometer BioTech A/S to develop a whole blood, point-of-care diagnostic product for the detection of collagen breakdown, an indicator of osteoporosis. Cortecs, calling the deal a "profit-sharing agreement," says that the development effort will combine its rapid diagnostic technologies with Osteometer's Cross-laps bone resorption marker technology. The companies will jointly develop the product, with clinical testing coordinated by The Center for Clinical and Basic Research in Denmark. Cortecs will manufacture the finished product, retain distribution rights for the U.K. and Australia and select distributors for other markets "from international corporations involved in the management of osteoporosis"...
You may also be interested in...
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.